How Much Do Clinical Trial Sites Get Paid?

The honest answer is that it depends, it can be real money, and it shows up later than you'd like. There's no flat rate for running a clinical trial. What a site earns is negotiated study by study, and it swings hard based on how complicated the protocol is and how many patients you actually enroll. The pieces are predictable once you know what to look for, so here's how the money really works.

What you're getting paid for

A sponsor doesn't put you on salary. You get paid for work done and patients enrolled, and the budget usually breaks into a few parts:

• Per-patient payments (the big one)
• Per-visit and per-procedure reimbursement
• A one-time start-up fee
• Screen-failure payments
• Pass-through costs like IRB fees, plus an overhead markup

Per-patient payments: the number that matters

This is where most of the money lives. The sponsor sets a per-subject budget, an amount you earn for each participant who completes the required visits or the full study, usually paid out quarterly or at milestones.

The range is wide. A simple later-phase study might pay a few thousand dollars per patient. A complex one, like an oncology or rare-disease trial with heavy monitoring, can pay a great deal more. You'll see figures online quoting $15,000 to $50,000 a patient. Treat those as illustrative, not typical. The real number is whatever that specific protocol's budget says.

Here's the part that actually determines your income: per-patient value times how many patients you enroll. A site that fits a study and enrolls well makes real money. A site that gets qualified and then enrolls nobody makes almost nothing, no matter how good the per-patient rate looked. Enrollment is the whole game.

The rest of the budget

• Start-up fee. A one-time payment, often a few thousand dollars, for the upfront protocol review, regulatory setup, and contracting.
• Per-visit and per-procedure reimbursement. Built from your staff's time and each test or procedure the protocol calls for.
• Screen-failure payments. Partial payment for patients you screen who turn out ineligible, so a round of screening isn't a total loss.
• IRB fees. Usually passed straight through rather than marked up.
• Overhead. An administrative markup on top of the direct costs.

The holdback, and why you won't see it all at once

Two things put a lag between the work and the deposit. First, sponsors hold back a slice of the payment, often around 10% and sometimes 15 to 20%, until the study closes and the data is reconciled. Second, payment terms tend to run net-30 to net-90, and late payment is one of the most common complaints sites have. So the money is real, but it's not fast. Don't budget it against an expense you have next month.

So what does a practice actually make?

It comes down to the study and your enrollment, which is why nobody can quote you a clean number. Realistically, one or two well-fitting studies that you enroll well can add a meaningful line of revenue on top of your practice, using patients you already see. It isn't passive, and it isn't instant. The biggest lever you control is picking studies your patients genuinely fit and then filling them.

The catch

The money only lands if you get selected for studies and enroll patients. Enrolling is on you. Getting selected is the harder problem, because sponsors route most studies through sites they already know. That's the real bottleneck for a new practice, and it's covered in how to become a clinical trial site.

If you want to see which studies are recruiting patients like yours right now, start a free TrialWave trial, no card required, or read the plain overview of getting paid to run trials.

---

This is general information, not financial, medical, legal, or regulatory advice. Payment terms vary by study and sponsor.